ARA-290
An 11-amino-acid EPO-derived peptide studied for neuropathic pain and tissue protection, without the red-cell-stimulating effects of full erythropoietin.
A synthetic peptide mimetic of erythropoietin's tissue-protective domain that activates the innate-repair heteromeric receptor (EPOR/βcR) selectively — producing anti-inflammatory and neuroprotective effects without erythropoiesis.
Mechanism of action
Selective agonist at the heteromeric erythropoietin/βcommon receptor (innate repair receptor), which is upregulated in injured or inflamed tissue. Activation reduces proinflammatory cytokine signaling, reduces apoptosis in stressed cells, and promotes tissue recovery. Lacks affinity for the homodimeric EPO receptor, so does not stimulate erythropoiesis or carry thrombotic risk.
Primary uses
- Sarcoidosis-associated small fiber neuropathy (Phase 2)
- Diabetic neuropathy (research)
- Chronic pain (research)
Typical dosing
Phase 2 sarcoidosis neuropathy trial used 4 mg daily for 28 days. No community-established dosing.
Regulatory status
Investigational. Developed by Araim Pharmaceuticals. Phase 2 completed for sarcoidosis-associated small fiber neuropathy; FDA Orphan Drug designation granted for sarcoidosis neuropathy.
References
- [clinical-trial] Dahan A, et al. "ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss." Mol Med, 2013;19:334-345.
- [pubmed] Brines M, et al. "Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin." Proc Natl Acad Sci USA, 2008;105:10925-10930.
Related peptides
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.